6,096 Shares in Exelixis, Inc. (NASDAQ:EXEL) Bought by Strategic Investment Advisors MI

Strategic Investment Advisors MI purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 6,096 shares of the biotechnology company's stock, valued at approximately $225,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Principal Securities Inc. increased its position in Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 373 shares during the last quarter. Truist Financial Corp grew its holdings in Exelixis by 31.7% during the 4th quarter. Truist Financial Corp now owns 18,169 shares of the biotechnology company's stock valued at $605,000 after purchasing an additional 4,378 shares during the last quarter. Y Intercept Hong Kong Ltd raised its position in Exelixis by 322.0% in the 4th quarter. Y Intercept Hong Kong Ltd now owns 56,522 shares of the biotechnology company's stock worth $1,882,000 after purchasing an additional 43,129 shares during the period. IFP Advisors Inc raised its position in Exelixis by 33.1% in the 4th quarter. IFP Advisors Inc now owns 16,529 shares of the biotechnology company's stock worth $550,000 after purchasing an additional 4,110 shares during the period. Finally, Amalgamated Bank lifted its stake in Exelixis by 1.7% in the fourth quarter. Amalgamated Bank now owns 142,147 shares of the biotechnology company's stock worth $4,733,000 after purchasing an additional 2,435 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on EXEL. Guggenheim set a $45.00 target price on Exelixis and gave the company a "buy" rating in a research note on Thursday, May 15th. Benchmark restated a "neutral" rating on shares of Exelixis in a report on Monday. HC Wainwright reiterated a "buy" rating and issued a $47.00 target price (up previously from $40.00) on shares of Exelixis in a research note on Thursday, June 12th. Morgan Stanley reiterated an "overweight" rating and set a $47.00 target price (up from $40.00) on shares of Exelixis in a research report on Wednesday, May 14th. Finally, Wells Fargo & Company reissued a "market outperform" rating on shares of Exelixis in a research note on Thursday, April 17th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and fourteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $43.22.

Insider Buying and Selling

In other Exelixis news, EVP Dana Aftab sold 1,508 shares of Exelixis stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $39.00, for a total value of $58,812.00. Following the transaction, the executive vice president now owns 693,181 shares in the company, valued at $27,034,059. The trade was a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Patrick J. Haley sold 126,383 shares of the stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $47.96, for a total transaction of $6,061,328.68. Following the sale, the executive vice president now directly owns 446,459 shares of the company's stock, valued at approximately $21,412,173.64. The trade was a 22.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 458,113 shares of company stock worth $21,024,817 in the last three months. 2.82% of the stock is owned by insiders.

Exelixis Stock Performance

Exelixis stock traded up $0.58 during mid-day trading on Friday, reaching $43.67. 3,523,886 shares of the company were exchanged, compared to its average volume of 2,448,811. The firm has a market cap of $11.91 billion, a P/E ratio of 19.85, a PEG ratio of 0.86 and a beta of 0.28. The business has a fifty day moving average of $41.07 and a 200 day moving average of $37.33. Exelixis, Inc. has a 12-month low of $21.82 and a 12-month high of $49.62.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.